

MW MediWound

Next-Generation Enzymatic Therapeutics
For Non-Surgical Tissue Repair



Global Partnerships



EscharEx[®]

Next-Generation Enzymatic Debridement
Drug Candidate for Chronic Wounds

Rapid, effective, safe debridement for
two indications: VLU and DFU

Easy to use topical application for all patient settings

Debrides chronic ulcers within 4-8 applications

Promotes granulation tissue and reduces bacteria & biofilm

Demonstrated superiority over SANTYL[®]

Targets a \$2B market

De-risked program: Validated technology; successful Phase 2 trials

Phase III VLU planned for H2 2024

Phase II/III DFU preparations currently underway

R&D collaborations with Mölnlycke, Solventum, MIMEDX



Validated Enzymatic Technology Platform



Solid Balance Sheet

\$51M cash

2023 revenues \$19M

2024 expected revenues \$24M

\$110M+ BARDA funding

\$15M+ DoD funding

€16M+ EIC funding

\$25M Strategic PIPE Financing

NexoBrid[®]

Disruptive Therapy for Burn Care
FDA, EMA approved

Poised to replace standard of care in eschar removal
for severe burns

Significantly reduces need for surgery and reduces blood loss

Topical application at bedside

Preserves viable tissue and improves patient outcomes (scar quality
and function)

Clinically and commercially validated

c-GMP sterile manufacturing facility to support global demand

Approved in 40+ countries; 12K+ patients treated to-date

